Assignee
EXUMA BIOTECH CORP
US·7 granted patents·13 pending applications·21 citations·filing 2017–2025
Top patents by PatentIndex Score
20 records- 0193US11325948B2Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPLEXUMA BIOTECH CORP·Filed 2020·Granted May 10, 2022·6 cites·27 claims
- 0292US12258574B2Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Granted Mar 25, 2025·1 cites·26 claims
- 0392US10596274B2Methods and compositions for transducing lymphocytes and regulated expansion thereofEXUMA BIOTECH CORP·Filed 2017·Granted Mar 24, 2020·10 cites·24 claims
- 0488US11111505B2Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2017·Granted Sep 7, 2021·3 cites·21 claims
- 0587US12325728B2Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of CD79A and CD79BEXUMA BIOTECH CORP·Filed 2022·Granted Jun 10, 2025·1 cites·26 claims
- 0680US2023257776A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 0777US2025236889A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2025·Application pending·0 cites
- 0876US2025026840A1Chimeric antigen receptors against axl or ror2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2024·Application pending·0 cites
- 0973US2021403952A1Methods and compositions for transducing lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1066US2025099612A1Viral particles with membrane-bound hyaluronidaseEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 1162US2023392139A1Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2023·Application pending·0 cites
- 1257US12187801B2Chimeric antigen receptors against AXL or ROR2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2018·Granted Jan 7, 2025·0 cites·22 claims
- 1357US2023357436A1Anti-idiotype compositions and methods of use thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1456US2023044451A1Methods and compositions for the delivery of modified lymphocytes and/or retroviral particlesEXUMA BIOTECH CORP·Filed 2022·Application pending·0 cites
- 1554US2023072955A1Chimeric antigen receptors to her2 and methods of use thereofEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1652US12590321B2Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2020·Granted Mar 31, 2026·0 cites·21 claims
- 1751US2023111159A1Methods and compositions for the delivery of modified lymphocyte aggregatesEXUMA BIOTECH CORP·Filed 2021·Application pending·0 cites
- 1850US2022340927A1Methods and compositions for the modification and delivery of lymphocytesEXUMA BIOTECH CORP·Filed 2020·Application pending·0 cites
- 1950US2021317408A1Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcsEXUMA BIOTECH CORP·Filed 2019·Application pending·0 cites
- 2045US2020397821A1Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereofEXUMA BIOTECH CORP·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →